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Targeted Skipping of a Single Exon Harboring a
Premature Termination Codon Mutation: Implications
and Potential for Gene Correction Therapy for
Selective Dystrophic Epidermolysis Bullosa Patients
Maki Goto1, Daisuke Sawamura1, Wataru Nishie1, Kaori Sakai1, James R. McMillan1, Masashi Akiyama1 and
Hiroshi Shimizu1
This study examined the feasibility of antisense oligoribonucleotide (AON) therapy for dystrophic
epidermolysis bullosa (DEB). AON was designed to induce skipping of a targeted exon containing a premature
termination codon mutation, resulting in restoration of the open reading frame. We targeted exon 70 of
COL7A1, as a recurrent mutation 5818delC in Japanese DEB patients was localized to exon 70. We found that one
AON induced effective skipping of normal exon 70 containing 16 amino acids. Attachment and migration
analyses showed that recombinant collagen without contribution of exon 70 was similar in effect to normal type
VII collagen. Next, we synthesized mutation-specific AON by deleting cytosine at 5818. Introduction of this AON
into DEB keratinocytes harboring 5818delC showed that the AON induced skipping of exon 70 in the abnormal
5818delC allele. Furthermore, 6.2% of DEB keratinocytes started to express type VII collagen in vitro after
application of the mutation-specific AON. Injection of the AON into rat model grafted with DEB keratinocytes
and fibroblasts induced a low amount of type VII collagen expression. We conclude that skipping of targeted
exons using mutation-specific AON may show potential for future gene therapy for DEB patients.
Journal of Investigative Dermatology (2006) 126, 2614–2620. doi:10.1038/sj.jid.5700435; published online 15 June 2006
INTRODUCTION
The transfer of normal genes into somatic cells is one strategy
to treat patients with genetic diseases. However, this strategy
still encounters problems including efficacy of gene transfer
rate and practical clinical safety. Thus, other strategies,
including pharmacological therapy or gene correction, are
receiving increasing attention.
Recently, studies of muscular dystrophy have demon-
strated the feasibility of modulating intron–exon splicing
using antisense oligoribonucleotides (AONs), which may
induce exon skipping, resulting in slightly shorter, but in-
frame, mRNA transcripts (Mann et al., 2001; Lu et al., 2003).
In muscular dystrophy caused by mutations in the dystrophin
gene, shorter transcripts found in patients with milder
phenotypes have a significantly longer life expectancy when
compared to the patients with a complete loss of dystrophin
expression (Monaco et al., 1988; England et al., 1990). These
observations have led to the idea of using AON to skip
abnormal, mutated exons to restore the open reading frame
and convert a severe phenotype into a milder form (Mann
et al., 2001; Lu et al., 2003). The mechanism of exon skipping
is based upon AON, small synthetic RNA molecules that are
designed to bind to specific sequences within the pre-mRNA
(Mayeda et al., 1990; Galderisi et al., 1999).
Dystrophic epidermolysis bullosa (DEB) is clinically
characterized by mucocutaneous blistering in response to
minor trauma, followed by scarring and nail dystrophy, and
patients generally exhibit tissue separation beneath the
lamina densa of the epidermal basement membrane where
anchoring fibrils are present in normal skin but structurally
compromised in DEB (Fine et al., 2000). DEB is caused by
mutations in the COL7A1 gene encoding type VII collagen,
the major component of anchoring fibrils (Uitto et al., 1995;
Fine et al., 2000). Several methods have achieved transfer of
normal COL7A1 into the patients’ skin (Chen et al., 2002;
Ortiz-Urda et al., 2002; Goto et al., 2006), but this has never
yet been extended to patients in clinical practice.
Previous report demonstrated an interesting DEB case
whose manifestation was milder than expected from muta-
tions in genomic DNA (McGrath et al., 1999). Further mRNA
analysis revealed that the mutation led to skipping of that
single exon and subsequent maintenance of the open reading
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frame. In addition, missense mutations are known to provide
unexpected COL7A1 splicing outcomes (Wessagowit et al.,
2005). The COL7A1 mutations causing single exon skipping
resulted in milder cases than the predicted Hallopeau–
Siemens recessive DEB phenotype (HS-RDEB) with nonsense
mutations (Terracina et al., 1998).
In this study, we have examined the feasibility of
using AON in targeted exon skipping to modulate COL7A1
splicing in such a manner that the translational open
reading frame can be restored in keratinocytes from DEB
patients.
RESULTS
Detection of exon 70 skipping in cultured keratinocytes
We targeted exon 70 for AON therapy as the recurrent
premature termination codon mutation 5818delC in DEB
patients was localized to exon 70 (Tamai et al., 1999;
Sawamura et al., 2005). We synthesized two potential AONs,
h70AON1 and h70AON2, which comprised full-length
phosphorothioate backbone and HPLC-purified 20-O-
methyl-modified ribose molecules (Figure 1a). To evaluate
the effects of h70AON1 and h70AON2 on COL7A1 skipping
of normal exon 70, we introduced them to HaCaT
keratinocytes or normal human epidermal keratinocytes,
and amplified COL7A1 cDNA by reverse transcriptase-PCR
(RT-PCR) with the forward primer on the border of exons 65
and 66, and a reverse primer on exon 72 (66–72 primer set).
The h70AON1 samples showed a single 347 bp band. In the
h70AON2 experiment, the samples showed a strong upper
347 bp band, whereas the lower 299 bp band was apparent
(Figure 1b). Sequence analysis revealed that the upper 347 bp
band consisted of exons 66, 67, 68, 69, 70, 71, and 72,
whereas a lack of exon 70 was found in the lower 299 bp
band. To semiquantify the amount of the lower and upper
bands, we subcloned the PCR product to the TA cloning
vector. The rate of the lower band to the upper band was
expressed as the exon skipping rate. The result showed that
the rates in samples of HaCaT cells and normal human
keratinocytes were 18.2 and 28.1%, respectively. Each value
represents the mean7SD of four samples.
These results indicate that h70AON2 could induce
skipping of exon 70. We simultaneously performed a
time–course experiment, in which COL7A1 expression in
cultured HaCaT cells was examined 8, 16, 24, 48, and
72 hours after h70AON2 transfer. We found the highest
expression of the 299 bp band at 16hours after AON transfer,
although the effect of AON was totally extinct 72 hours after
the transfer (Figure 1c). We obtained the samples 16 hours
after transfer of h70AON2 for further experiments.
Detection of exon 70 skipping in vivo
To simulate AON therapy in clinical practice, we
transplanted human skin onto a nude rat and then injected
30 mg of h70AON2 to the graft. Saline was injected in a
control. After 16 hours, the skin biopsies were taken from
the injected site and were subjected to RT-PCR analysis.
RT-PCR with the 66–72 primer set amplified a 347 bp strong
band containing exon 70 and a weak signal of 299 bp band
without exon 70 from the treated sample, whereas the control
sample showed 347 bp band alone (Figure 2). We also
applied 0.3 or 3 mg of h70AON2 to the graft, resulting in no
signal of 299 bp band (data not shown). TA cloning of the
30 mg h70AON2 samples showed that the proportion of the
lower band to the upper bands was 12.2%. To verify exon 70
skipping, we synthesized a 70D primer set with a forward
primer on border of exons 63 and 64, and reversel primer on
the border of exons 69 and 71. RT-PCR amplification with the
70D primer set detected a 305 bp band in only the AON-
treated samples, which were indicative of exon skipping of
70 (Figure 2).
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Figure 1. Detection of exon 70 skipping in cultured keratinocytes. The
recurrent premature termination codon mutation 5818delC in DEB patients
was localized to exon 70. We introduced h70AON1 and h70AON2 into
HaCaT keratinocytes or normal human keratinocytes (NHEK), and amplified
COL7A1 cDNA by RT-PCR with the 66–72 primer set. (a) Sequences of
h70AON1 and 2 are shown. (b) The h70AON1 samples (1) showed a single
347 bp band containing exon 70 (black arrow). The h70AON2 samples (2)
showed an upper strong 347 bp band with exon 70 (black arrow), whereas the
weaker lower 299 bp band without exon 70 (white arrow) was apparent. Only
the 347 bp band was found in control samples without AON treatment (Cont).
(c) We performed a time–course experiment, in which COL7A1 expression in
cultured HaCaT cells was examined 8, 16, 24, 48, and 72 hours after
h70AON2 transfer. We found the highest expression of the 299 bp band at the
16 hours after AON transfer although the effect of AON was totally extinct
72 hours after the transfer.
347 bp 305 bp
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Cont AON Cont AON
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Figure 2. Detection of exon 70 skipping in vivo. We transplanted human skin
to a nude rat and then injected 30 mg of h70AON2 AON into the graft. After
16 hours, the skin biopsies were taken from the injected site and were
subjected to RT-PCR analysis. (a) RT-PCR with the 66–72 primer set amplified
a 347 bp strong band (black arrow) containing exon 70 and a weaker signal
of 299 bp band (white arrow) without exon 70 from the (AON)-treated
sample, whereas the control sample showed a 347 bp band alone (Cont).
(b) RT-PCR amplification with the 70D primer set detected a 305 bp band
only in AON-treated samples. The AON lane seemed to have the higher
molecular weight band in addition to the 305 bp COL7A1 band. However,
subcloning of PCR product to a TA cloning vector (Invitrogen, Carlsbad, CA)
could not detect the corresponding COL7A1 cDNA and we thought it to
be a PCR artifact.
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Assays for type VII collagen without exon 70
There is a possibility that the deletion of 16 amino acids,
which are encoded by exon 70, may abolish some of the
functions of type VII collagen. Therefore, we prepared
retrovirus vector containing COL7A1 cDNA without exon
70, and introduced the gene to keratinocytes from HS-RDEB
patient who harbored heterozygous COL7A1 5818delC and
1474del8 mutations, and showed no expression of type VII
collagen in immunofluorescence level as mentioned below
(Goto et al., 2006). The Western blot of the supernatant
showed that HS-RDEB keratinocytes began to express type
VII collagen after gene introduction (Figure 3a). The amounts
of secreted collagen were almost identical in culture media
between the normal COL7A1 and COL7A1D70 samples.
Subsequently, the cultured keratinocytes supernatant and the
keratinocytes themselves were used for in vitro and in vivo
studies. Cell migration assay using normal keratinocytes
showed that the supernatants both with COL7A1 and
COL7A1D70 samples had a similar effect on the migration
of normal keratinocytes (Figure 3b). The cell adhesion assay
also demonstrated that COL7A1D70 supernatant had almost
the same adhesive properties for the cells as normal COL7A1
(Figure 3c). Furthermore, we constructed artificial skin grafts
using untreated HS-RDEB fibroblasts and HS-RDEB keratino-
cytes transduced with COL7A1 and COL7A1D70, and then
applied them to a nude rat model. Ultrastructural analysis of
the grafts showed formation of anchoring fibrils in both
samples with COL7A1 and COL7A1D70 samples (Figure 4).
These results demonstrated that type VII collagen that lacks
16 amino acids of exon 70 might have similar properties to
normal type VII collagen, suggesting that exon 70 skipping by
AON is promising.
Elucidation of AON specific for 5818delC mutation
We designed mutation-specific AON hm70AON by deleting
cytosine at 5818 (Figure 5a). Then we introduced hm70AON
to normal human keratinocytes and HS-RDEB keratinocytes
and performed the following RT-PCR analysis. The sample
from HS-RDEB keratinocytes showed two PCR bands with or
without exon 70, whereas a strong upper single band was
observed in of the sample from normal human keratinocytes
(Figure 5b). This indicated that the hm70AON induced
skipping of exon 70 predominantly in abnormal allele with
the 5818delC mutation. The sample from HS-RDEB keratino-
cytes without the AON treatment as control also showed the
single band. TA cloning of the PCR samples showed that the
exon skipping rates of HS-RDEB and normal keratinocyte
samples were 18.5 and 1.3%, respectively; therefore,
hm70AON induced skipping of exon 70 predominantly in
abnormal allele with 5818delC. This HS-RDEB patient
harbored heterozygous COL7A1 5818delC and 1474del8
mutations, and RT-PCR analysis using the keratinocyte cDNA
showed no naturally occurring skipping of exon 70 contain-
ing the frameshift mutation (Figure 5b). Immunofluorescence
analysis demonstrated using type VII collagen no expression
of type VII collagen (Figure 5c) and ultrastructural study
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Figure 3. Assays for the type VII collagen without exon 70. We prepared
retrovirus vectors with normal COL7A1 cDNA (Wild) or COL7A1 cDNA
without exon 70 (D70), and introduced the gene into DEB keratinocytes,
which showed no expression of any type VII collagen. (a) The Western blot of
the supernatant showed that the amount of secreted type VII collagen in the
culture media was almost similar to that of the normal COL7A1 and
COL7A1D70 samples. Cont: no transfection. (b) Cell migration assay showed
that the supernatants from both COL7A1 and COL7A1D70 samples had a
similar effect on normal human keratinocyte migration. (c) The cell adhesion
assay also demonstrated that COL7A1D70 supernatant had almost the same
adhesive ability for normal keratinocytes as that of COL7A1 (Figure 3). Each
value represents mean7SD of six samples. *Po0.01: significant difference
between cont versus wild or cont versus D70 samples.
Cont
∆70
Wild
Figure 4. Formation of anchoring fibrils containing COL7A1D70. We
constructed artificial skin grafts using DEB fibroblasts and keratinocytes
transduced with wild-type COL7A1 or COL7A1D70, and then grafted them
onto a nude rat model. Ultrastructural analysis of the grafts showed that
formation of anchoring fibrils could be identified in both samples with
COL7A1- and COL7A1D70-transfected cells. Although no obvious anchoring
fibrils were observed in control grafts with untransfected DEB keratinocytes
alone (Cont), there were wisp-like structures below the lamina densa.
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revealed markedly reduced anchoring fibrils in the basement
membrane zone (data not shown).
Rescue of type VII collagen expression in DEB keratinocytes
in vitro
To examine COL7A1 expression in the HS-RDEB keratino-
cytes treated with hm70AON, we transfected hm70AON into
cultured HS-RDEB keratinocytes and stained with an anti-
body against type VII collagen (LH7.2). Some cells were
shown to express type VII collagen (Figure 6). The rate of cell
expression per total number of cells was 6.2%. We
transfected h70AON1 and h70AON2, but no cells showed
collagen VII immunoreactivity (data not shown).
Injection of hm70AON to the graft from DEB keratinocytes and
fibroblasts
To determine the therapeutic feasibility of AON therapy in
clinical practice, we constructed an artificial skin graft using
HS-RDEB keratinocytes and fibroblasts, transplanted the graft
to a nude rat, and then injected 30 mg of hm70AON to several
portions of the graft. Saline was injected as a control. RT-PCR
with the 66–72 primer set amplified only 347 bp band
containing exon 70 and a weak signal for the 299 bp band
without exon 70 from the treated sample (Figure 7a). The 70D
primer set detected 305 bp band only in AON samples,
indicating exon skipping of 70 (Figure 7b). Control samples
did not express either 299 bp band by the 66–72 primer set, or
305 bp band using the 70D prime set. Furthermore,
we performed immunohistochemical analysis of the
treated graft with a type VII collagen antibody and could
detect definite but intermittent linear dermal–epidermal
junction immunoreactivity in the majority of treated samples,
whereas no immunoreactivity was observed in control
samples (Figure 7c and d).
DISCUSSION
Type VII collagen, a non-fibrillar collagen, is a major
component of anchoring fibril loop structures beneath the
epidermal basement membrane (Uitto et al., 1992; Burgeson,
1993). Cloning of collagen VII cDNA demonstrated a primary
sequence of 2,944 amino acids and the basic organization of
the functional domains (Christiano et al., 1994a). Subsequent
genomic cloning has highlighted the structural organization
of the collagen VII gene (COL7A1) (Christiano et al., 1994b).
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Figure 5. Elucidation of AONs specific for 5818delC mutation. We
introduced mutation-specific AON hm70AON into normal human keratino-
cytes and DEB keratinocytes and performed the following RT-PCR analysis.
(a) Sequences of mutation-specific AON hm70AON are shown. (b) The
sample from DEB keratinocytes showed two PCR bands with exon 70 (347 bp)
or without exon 70 (299 bp), whereas there was little or no lower band
(299 bp) observed in the normal human keratinocytes sample (NHEK). Cont:
the sample from DEB keratinocytes without the AON treatment. This HS-
RDEB patient harbored heterozygous COL7A1 5818delC and 1474del8
mutations and RT-PCR analysis showed no naturally occurring skipping of
exon 70 containing the frameshift mutation. (c) Immunofluorescence analysis
of the patient using type VII collagen antibody demonstrated no expression of
type VII collagen (the upper panel). The lower panel shows the expression
from normal control. Arrows indicate epidermal–dermal junction.
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Figure 7. Injection of hm70AON into the graft from DEB keratinocytes and
fibroblasts. We constructed an artificial skin graft using HS-RDEB keratino-
cytes and fibroblasts, transplanted the graft onto a nude rat, and then injected
hm70AON into the graft. Saline was injected in a control. (a) RT-PCR with the
66–72 primer set amplified a 347 bp band containing exon 70 and a weak
signal with the 299 bp band without exon 70 from the treated sample. (b) The
70D primer set detected only the 305 bp band in AON-treated samples.
(c) Immunohistochemical analysis of the treated graft with type VII collagen
antibody detected discontinuous, linear immunoreactivity along the
dermal–epidermal junction (arrows). (d) Saline was injected in a control
graft. Original magnification (c, d)  200.
Cont AON
Figure 6. Rescue of type VII collagen expression in DEB keratinocytes
in vitro. We transfected the hm70AON (AON) into cultured HS-RDEB
keratinocytes and stained with an antibody against type VII collagen.
Cont: no treatment of AON. Some cells were shown to express type VII
collagen after the treatment (arrows).
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This study has examined the feasibility of targeted exon
skipping using AON. As the intron/exon organization of
COL7A1 contained 118 multiple short exons, deletion of one
shorter exon may not significantly interfere with type VII
collagen function. In fact, a mutation study revealed that
several COL7A1 splice-site mutations causing skipping of one
exon resulted in a milder phenotype than the expected HS-
RDEB that harbors nonsense mutations causing a lack of
COL7A1 expression (Terracina et al., 1998). Furthermore,
DEB mutations were frequently found in exons encoding
collagenous domains and the nucleotide number of these
exons is definite multiples of 3. This indicated that abolish-
ment of exons restored an open leading flame of COL7A1.
These characteristic features of the gene structure encouraged
the start of research into the possibility of AON skipping
therapy.
COL7A1 mutation database demonstrates presence of
recurrent COL7A1 mutation, and AONs, which are suitable
for recurrent mutation, of course, are applicable for more
patients than AONs for rare mutation. Thus, this study
targeted exon 70 AON therapy, as the recurrent premature
termination codon mutation 5818delC in exon 70 was found
in more than 20% of recessive DEB sufferers (Tamai et al.,
1999; Sawamura et al., 2005). We first synthesized two
potential AONs, h70AON1 and h70AON2, for exon 70 and
the results indicated that h70AON2 was able to induce
skipping of exon 70 in vitro and in vivo. To understand the
effect of exon 70 deletion on the essential functions of type
VII collagen, we constructed COL7A1 cDNA without exon
70 (COL7A1D70) and introduced this defective gene to HS-
RDEB in vitro and in vivo. The results of attachment and
migration analyses showed that the deleted collagen had an
apparently similar function to the normal collagen. Next, we
examined the ability of the defective collagen to form
anchoring fibrils. To eliminate internal expression of type
VII collagen, we used keratinocytes and fibroblasts from HS-
RDEB who exhibited no COL7A1 expression and failed to
form any anchoring fibril-like structures in patient skin.
Ultrastructural examination of the skin graft treated with
COL7A1D70 demonstrated anchoring fibril formations in the
sublamina densa. These results indicate that type VII
collagen, lacking the 16 amino-acid sequences from exon
70, exhibits a remarkably near-normal assay similar to the
normal type VII collagen.
As the sequence of h70AON2 was located at the
5818delC mutation site, we synthesized a mutation-specific
AON hm70AON to match the sequence with deletion of
5818 cytosine. After transfection of hm70AON into HS-RDEB
harboring the 5818delC defect, RT-PCR demonstrated
effective exon 70 skipping. However, as predicted, when
this AON was introduced to normal human keratinocytes, we
found little skipping against exon 70 in the wild COL7A1
allele. Some recessive DEB patients harbor heterozygous
mutations 5818deC and missense mutations, which would
not interfere with the function of this type VII collagen. In this
case, hm70AON benefited by not altering the expression of
COL7A1 on the other allele. Further immunofluorescence
studies using HS-RDEB cell culture systems showed that
transfection of hm70AON could rescue type VII collagen
expression in patient’s keratinocytes. Approximately, 6%
cells began to synthesize type VII collagen.
Finally, we constructed artificial HS-RDEB skin from the
patient’s keratinocytes and fibroblasts, and introduced
hm70AON to the graft. RT-PCR analysis using the 66–72
primer set and the 70D primer set detected the presence of
exon 70 skipping in the treated graft. Furthermore, immuno-
fluorescence using type VII antibody demonstrated the
positive expression of type VII collagen along restricted parts
of the dermal–epidermal junction. Although we obtained the
samples from several specimens and carried out electron
microscopic analysis, we could not observe obvious anchor-
ing fibrils ultrastructurally. We might examine no section
corresponding to the restricted immunoreactive parts.
We recently suggested that fibroblasts might be a better
gene therapy target of DEB treatment than keratinocytes
(Goto et al., 2006). The majority of collagen VII in vivo are
thought to originate from keratinocytes because the level of
COL7A1 expression in the epidermis was much higher than
that in the dermis. However, when COL7A1 expressions of
keratinocytes and fibroblast were almost equal after retroviral
transfer of COL7A1, the gene-transferred fibroblasts supplied
a higher amount of collagen VII to the new dermal–epidermal
junction than the gene-transferred keratinocytes (Goto et al.,
2006). The AON therapy cannot generate an additional
COL7A1 expression, and it just modifies the existing
expression. So, we think that AON transferred into keratino-
cytes gives predominant therapeutic effect in this study.
Finally, disadvantages of this AON approach for DEB are
proposed. First, the effect disappeared immediately because
AON is easily degraded in the cells. This study showed that
the effect of AON was totally extinct 72 hours after the
transfer of AON in vitro. Second, the method cannot induce
the perfect full-length collagen VII. There is the possibility
that in-frame exon skipping may lead to a dominant-negative
interference. In fact, a 16-bp internal deletion in the COL7A1
gene leading to in-frame exon skipping caused dominant
phonotype of DEB (Cserhalmi-Friedman et al., 1998). Third,
transfer efficacy of AON to the skin is relatively low. Kinetic
analysis of oligonucleotide topically applied to mouse skin
showed early follicular localization, diffusion of the oligo-
nucleotide from the mid-follicle, and subsequent dermal
accumulation (Dokka et al., 2005). Our study transfer
efficacy was low in our skin graft experiment, but application
of AON to actual skin may show a higher transfer efficacy,
perhaps owing to the increased presence of skin appendages.
In conclusion, we believe that improvement of these points
enables this strategy to be applicable to clinical practice.
MATERIALS AND METHODS
AON
We selected exon 70 for AON therapy as the recurrent premature
termination codon mutation 5818delC was present in exon 70 in
DEB patients (Tamai et al., 1999; Sawamura et al., 2005). We
designed a potential AON for exon skipping using the RNA mfold
version 3.1 server (Zuker, 2003), and synthesized a full-length phospho-
rothioate backbone and HPLC-purified 20-O-methyl-modified ribose
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molecules. The sequences of the synthesized AONs were as follows:
h70AON1, 50-CCACGCUCUCCAGGGAG-30 and h70AON2, 50-
CUUCCAGGCUCUCCUCGC-30 for human type VII collagen:
hm70AON, 50-CGCACACUUCCAGGC-30 for 5818delC mutation
(Figures 1a and 5b).
Cell culture and AON transfection
The human keratinocyte HaCaT cell line was maintained in DMEM
with 10% fetal bovine serum. Primary keratinocytes were isolated
and grown in the presence of mitomycin C-treated 3T3 feeder layer
(Rheinwald and Green, 1975). Briefly, keratinocytes, which were
obtained from HS-RDEB patient skin biopsies and healthy controls,
were cultured on feeder layers of mitomycin C-treated mouse 3T3
fibroblasts in DMEM: Ham’s F-12 (3:1) supplemented with 10% fetal
bovine serum, 5mg/ml insulin, 10 ng/ml EGFR, 0.4mg/ml hydro-
cortisone, and 8 ng/ml cholera toxin. Human fibroblasts were also
obtained from a skin biopsy from an HS-RDEB patient and healthy
controls, and were cultured in DMEM with 10% fetal bovine serum.
This HS-RDEB patient harbored heterozygous COL7A1 5818delC
and 1474del8 mutations, and showed no expression of type VII
collagen (Goto et al., 2006).
After changing of the medium to serum-free Opti-MEM (Gibco
Invitrogen, Grand Island, NY), we transfected the AONs into the
cells using Lipofectamine 2000 (Gibco Invitrogen) according to the
manufacturer’s protocols. In all experiments, the cells were exposed
to transfection reagent for 16 hours and the media were replaced
with fresh growth medium.
Graft experiments
We transplanted artificial and normal skin onto a nude rat. Briefly,
106 HS-RDEB fibroblasts were seeded into a collagen sponge scaffold
and maintained in DMEM with 10% fetal bovine serum. Confluent
cultures containing 106 HS-RDEB keratinocytes were treated with
dispase (1 nU/ml; Godo Shusei, Tokyo, Japan), and the floating
epidermal sheet placed on the collagen sponge. In nude rats (F344/N
Jcl-rnu; CLEA Japan, Tokyo, Japan), the sites for transplantation were
prepared by excising a 2 cm2 area of dorsal skin. The collagen sponge
containing the fibroblasts was placed into the skin wound and then
the epidermal sheet overlaid on the collagen sponge. In other
experiments, normal skin samples were obtained from the abdomens
of patients undergoing reconstructive plastic surgery at the Hokkaido
University Hospital. Each skin sample was placed directly on the
2 cm2 wound on the nude rat. Afterwards, an occlusive dressing was
quickly placed over the graft to hold it in position and to prevent it
from drying. After 7 days, the dressing was removed, and then 30mg
AON was diluted in normal saline to a final volume of 150ml and
injected into several portions of the grafts. After 16 hours, the skin
biopsies were taken from the injected site and were subjected to RT-
PCR analysis as the in vitro time–course study indicated the highest
expression of the exon-skipping band at 16 hours after AON transfer.
Informed consents were obtained from all individual subjects in
this study. The protocols were approved by the Ethical Committee at
Hokkaido University Graduate School of Medicine. This study was
conducted according to the Declaration of Helsinki Principles.
RNA isolation and RT-PCR analysis
Skin samples were taken from the rodent model and were first
homogenized using a Polytron homogenizer. Total RNA was
extracted from skin samples and cultured cells using an RNeasy
RNA extraction kit (Qiagen, Hilden, Germany). First strand cDNA
was synthesized with reverse transcriptase (Life Sciences, St
Petersburg, FL) using an oligo-dT primer. To determine the splice-
specific expression of exon 70, we designed the forward PCR primer
on the border of exons 65 and 66, and the reversel primer on exon
72. The amplification conditions were carried out using the 66–72
primer set, forward 50-GAAGGGAGAGAAAGGAGATT-30 and re-
versel 50-GGAAGCTACCAGAGCTCTCA-30, for 35 cycles of reaction
at 941C for 1 minute, 581C for 1 minute, and 721C for 1 minute. In
addition, to verify the skipping of exon 70, we set the forward primer
on the border of exons 63 and 64, and reversel primer on the border
of exons 69 and 71. The amplification conditions were carried out
with the 70D primer set, forward 50-TGGATTACCGGGAAAGCCAG-
30 and reversel 50-GATCCACATTCTGCTCCCCT-30, for 35 cycles of
reaction at 941C for 1 minute, 581C for 1 minute, and 721C for
1 minute. The PCR products were fractionated on 2% agarose gels
and directly sequenced by di-deoxy dye-terminator method using an
automated sequencer (ABI Prism Genetic Analyzer 3100, PE
Biosystems, Foster city, CA). When several bands were found, we
subcloned the PCR sample into a TA cloning vector (Gibco
Invitrogen). After transformation of the bacteria, we picked up 50
colonies and examined the inserts to semiquantify the amounts of
the bands. The rate of the lower band to the upper band was
expressed as the exon skipping rate. Each value represents the
mean7SD of four samples. Moreover, the PCR products were
directly sequenced by di-deoxy dye-terminator method using an
automated sequencer (ABI Prism Genetic Analyzer 3100, PE
Biosystems, Foster city, CA).
Immunostaining and Western blot analysis. Cultured, trans-
fected cells were fixed with 2% paraformaldehyde in phosphate-
buffered saline, and were then incubated with the mAb LH7.2
against the NC1 domain of collagen type VII (Chemicon, Temecula,
CA). The secondary antibody was FITC-conjugated goat anti-mouse
IgG and preparations were examined under a fluorescence micro-
scope. Subconfluent keratinocyte cultures were fed for 48 hours with
serum-free medium supplemented with 50 mg/ml ascorbic acid. For
SDS-PAGE analysis, the culture medium was treated with Amicon
Ultra-100,000 Centrifugal Filter Devices (Millipore, Bedford, MA) for
protein concentration and desalting. The samples were separated on
a 5% polyacrylamide gel under reducing conditions. Immunoblot-
ting analysis was performed using the LH7.2 mAb followed by the
secondary antibody goat anti-mouse IgG conjugated to peroxidase.
The resultant complexes were processed for Phototope horse radish
peroxidase Western Blot Detection System (Cell Signaling, Beverly,
MA) according to the manufacturer’s protocol.
Assays for the type VII collagen without exon 70
Introduction of h70AON2 into keratinocytes induced skipping of
exon 70 (see the Results section). We prepared cDNA from the
introduced keratinocytes and amplified cDNA without exon 70
(COL7A1D70). A retroviral vector pDON(D) was created by remo-
ving the Simian virus-40 promoter and Neo gene from pDON-AI
(Takara, Kyoto, Japan). The genes COL7A1 and COL7A1D70 were
inserted into pDON(D) and these retrovirus plasmids were intro-
duced into the amphotropic amphopack-293 packaging cells
(Clontech, Palo Alto, CA) using calcium phosphate co-precipitation.
www.jidonline.org 2619
M Goto et al.
COL7A1 Exon Skipping
The viral particles were recovered from the cell culture medium
48 hours later and applied to cultured DEB keratinocytes that failed
to express COL7A1. The supernatant of the cultured keratinocytes
and the keratinocytes themselves were used for in vitro and in vivo
studies.
The methods for the cell migration assay and cell adhesion assay
were performed as described previously (Tsuda et al., 2002). Briefly,
culture dishes were treated with conditioned supernatants from
cultured HS-RDEB keratinocytes transduced with COL7A1 and
COL7A1D70 for 24 hours. Control dishes were treated with culture
medium. After the plating of normal keratinocytes for 48 hours on
the treated dishes, the cells were scraped off using a 200 ml yellow
pipette tip. Subsequently, at 8, 16, and 24 hours, the number of cells
that had moved from the base line into the scratched area was
measured. In addition, normal keratinocytes were allowed to attach
for 1.5 hours on the treated dishes and, after removal of unattached
cells, washed and fixed with 70% ethanol for 10 minutes. Adherent
cells were then stained with crystal violet and the number of the cells
was measured.
The collagen sponge containing HS-RDEB fibroblasts was placed
on skin wound of nude rat and the confluent cultures of 106 HS-
RDEB keratinocytes transduced with COL7A1 and COL7A1D70
were overlaid on the collagen sponge, as mentioned above. After 8
weeks, the skin biopsies were taken from the graft and subject to
routine ultrastructural analysis.
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